The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells

Por Kusio-Kobialka, Monika, Podszywalow-Bartnicka, Paulina, Peidis, Philippos, Glodkowska-Mrowka, Eliza, Wolanin, Kamila, Leszak, Grzegorz, Seferynska, Ilona, Stoklosa, Tomasz, Koromilas, Antonis E., Piwocka, Katarzyna
Publicado em 2012

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

Por Oplustilova, Lenka, Wolanin, Kamila, Mistrik, Martin, Korinkova, Gabriela, Simkova, Dana, Bouchal, Jan, Lenobel, Rene, Bartkova, Jirina, Lau, Alan, O’Connor, Mark J., Lukas, Jiri, Bartek, Jiri
Publicado em 2012

Correction to Oplustilova L, et al. Cell Cycle Volume 11, Issue 20; pp. 3837–50

Por Oplustilova, Lenka, Wolanin, Kamila, Mistrik, Martin, Korinkova, Gabriela, Simkova, Dana, Bouchal, Jan, Lenobel, Rene, Bartkova, Jirina, Lau, Alan, O’Connor, Mark J., Lukas, Jiri, Bartek, Jiri
Publicado em 2013

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity

Por Moudry, Pavel, Watanabe, Kenji, Wolanin, Kamila M., Bartkova, Jirina, Wassing, Isabel E., Watanabe, Sugiko, Strauss, Robert, Troelsgaard Pedersen, Rune, Oestergaard, Vibe H., Lisby, Michael, Andújar-Sánchez, Miguel, Maya-Mendoza, Apolinar, Esashi, Fumiko, Lukas, Jiri, Bartek, Jiri
Publicado no J Cell Biol (2016)